According to the Welt am Sonntag newspaper, BioNTech has recently been contacted by a number of industry players, but is not interested in a takeover, as reported in This Is Money.
Regulators in Germany recently approved human trials of a potential coronavirus vaccine that BioNTech is developing with Pfizer.
BioNTech chief executive Ugur Sahin said the company had been approached by several players in the industry, without saying what the subject of the approaches were.
"Takeovers are out of the question for the majority shareholders and for us anyway. Our vision is to build a biopharmaceutical company that addresses the medical needs of the 21st century," Sahin remarked.
To read more NewsPoints articles, click here.